These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 8427271)
1. FDA proposes more stringent pediatric-use labeling of prescription drug products. Am J Hosp Pharm; 1993 Jan; 50(1):13, 16. PubMed ID: 8427271 [No Abstract] [Full Text] [Related]
2. FDA proposes more stringent pediatric-use labeling of prescription drug products. Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434 [No Abstract] [Full Text] [Related]
3. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule. Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880 [TBL] [Abstract][Full Text] [Related]
4. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry. Karst KR Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732 [No Abstract] [Full Text] [Related]
5. Requirements on content and format of labeling for human prescription drug and biological products. Final rule. Food and Drug Administration, HHS Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698 [TBL] [Abstract][Full Text] [Related]
6. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics. Novak E; Allen PJ Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005 [TBL] [Abstract][Full Text] [Related]
7. Prescription drug products; revocation of patient package insert requirements--Food and Drug Administration. Final rule. Fed Regist; 1982 Sep; 47(173):39147-55. PubMed ID: 10258154 [TBL] [Abstract][Full Text] [Related]
9. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule. Food and Drug Administration, HHS Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084 [TBL] [Abstract][Full Text] [Related]
11. Content and format of labeling for human prescription drugs; pregnancy labeling; public hearing--FDA. Notice of public hearing; request for comments. Fed Regist; 1997 Jul; 62(147):41061-3. PubMed ID: 10169832 [TBL] [Abstract][Full Text] [Related]
12. Uses of drugs not described in the package insert (off-label uses). Committee on Drugs. American Academy of Pediatrics Pediatrics; 2002 Jul; 110(1 Pt 1):181-3. PubMed ID: 12093968 [TBL] [Abstract][Full Text] [Related]
13. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule. Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285 [TBL] [Abstract][Full Text] [Related]
14. FDA notifications. New labeling for Videx pediatric powder. AIDS Alert; 2009 Aug; 24(8):94-6. PubMed ID: 19705588 [No Abstract] [Full Text] [Related]
15. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice. Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155 [TBL] [Abstract][Full Text] [Related]
17. Regulating off-label drug use--rethinking the role of the FDA. Stafford RS N Engl J Med; 2008 Apr; 358(14):1427-9. PubMed ID: 18385495 [No Abstract] [Full Text] [Related]
18. Off-label or off-limits? Ratner M; Gura T Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236 [No Abstract] [Full Text] [Related]
19. Should expiration dates be required on patients' prescription labels? Hadeler F Am Pharm; 1986 Aug; NS26(8):30-5. PubMed ID: 3776829 [No Abstract] [Full Text] [Related]
20. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related] [Next] [New Search]